Below, find the full data for April’s 10 biggest pharma ad spenders, as compiled by iSpot.TV. 1. Skyrizi Movement: Up three spots What is it? AbbVie’s immunology drug Est. national TV ad spend ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Relying on lightweight and light-coverage picks for her go-to everyday makeup look, one of Meghan's firm favourites is this Yves Saint Laurent Touche Éclat Illuminating Pen, which she uses to ...

Resets are common in baseball, whether in the ‘pen or Triple-A. “I honestly don’t know how to look at it other than take the opportunity to take the ball when it’s given to me and try to ...

After pitching the first perfect game in program history and striking out 11 on April 16 in Pen Argyl’s 5-0 win over the Crusaders, Bradley held Notre Dame to six hits and one earned run as she ...

The Illinois-based company ABBV, which is the parent of drug brands Botox and Skyrizi, echoed recent comments from fellow drugmaker Johnson & Johnson JNJ. AbbVie also brought up issues it had with ...

1 Life of Fund (LOF) if performance is less than 10 years. Fund inception date: 07/14/1981. 2 This expense ratio is from the most recent prospectus and generally is based on amounts incurred ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...

Johnson & Johnson JNJ and AbbVie ABBV are two major U.S. pharmaceutical companies with robust pipelines and global operations. Both companies have a strong presence in immunology, oncology and ...

IQVIA also spotlighted AbbVie’s Skyrizi as the highest contributor of immunology spending growth, largely in its psoriasis indication. GLP-1 drugs on their own accounted for 29% of the spending ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.